Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1295 - Expression of CT antigens in periampullary carcinomas patients: Potential minimally-invasive biomarkers for diagnosis

Date

17 Dec 2016

Session

Poster lunch

Presenters

Shivam Singh

Citation

Annals of Oncology (2016) 27 (suppl_9): ix9-ix18. 10.1093/annonc/mdw574

Authors

S. Singh1, A. Saraya2, R. Sharma1

Author affiliations

  • 1 Biotechnology, Guru Gobind Singh Indraprastha University, 110078 - Delhi/IN
  • 2 Gastroenterology, All India Institute of Medical Sciences, 110029 - Delhi/IN
More

Resources

Abstract 1295

Background

Detection of periampullary carcinoma (PAC) by modern diagnostic techniques is less promising. Cancer Testis Antigens (CTAs) are found to be expressed by normal germ cells only. Recent studies showed aberrant expression of certain CTAs viz. Sp17, NY-ESO-1, SCP1 and GAGE in various cancers. However, their expression have not yet been analysed in PAC.

Methods

Real time PCR was done to assess the mRNA expression of Sp17, NY-ESO-1, SCP1 and GAGE in tissues and sera samples collected from consented PAC patients and normal subjects. Moreover, circulating levels of anti-Sp17 and NY-ESO-1 antibodies were determined in sera of PAC patients and normal subjects using ELISA. Immunohistochemical analysis of Sp17 protein in PAC tissues was also carried out.

Results

Significantly increased mRNA expression of Sp17, NY-ESO-1, SCP1 and GAGE was found in 70%, 75%, 80% and 70%, respectively, PAC tissues when compared with distant matched non-malignant tissues (P 

Conclusions

In the present study, increased expression of all the CTA genes was observed in both tissues and sera of PAC patients emphasizing its diagnostic potential. Moreover, elevated circulating levels of anti-Sp-17 and NY-ESO-1 antibodies were observed in serum of PAC patients with good sensitivity and specificity and could discriminate these patients from healthy individuals. In addition to these, expression of Sp17 protein in PAC tissues confirms the high circulating levels of anti-Sp17 antibody in serum of PAC patients.

Clinical trial indentification

Legal entity responsible for the study

Dr Rinu Sharma (Principal Investigator)

Funding

Department of Science of Technology, India

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings